Results 231 to 240 of about 3,396,597 (298)

MRDDA: a multi-relational graph neural network for drug-disease association prediction. [PDF]

J Transl Med
Chen C, Zhou Y, Li Y, Xu J, Li D, Wang L.   +5 more
europepmc   +1 more source

Development of 4T1 breast cancer mouse model system for preclinical carbonic anhydrase IX studies

FEBS Open Bio, EarlyView.
Carbonic anhydrase IX (CAIX) is a well‐recognised therapeutic target and prognostic biomarker in cancer. We developed and characterised a robust murine breast cancer model system that is suitable for CAIX studies in vitro and in vivo—it comprises both CAIX‐positive and CAIX‐negative controls and provides a solid platform for the comprehensive ...
Zane Kalniņa, Ilva Liekniņa, Svetlana Koteloviča, Ramona Petrovska, Gediminas Žvinys, Agne Petrosiute, Asta Zubrienė, Matīss Toms Laugalis, Vendija Skeltona, Juris Jansons, Madara Kreishmane, Edita Čapkauskaitė, Daumantas Matulis, Kaspars Tārs   +13 more
wiley   +1 more source

Gender differences in drug-induced precocious puberty: a real-world analysis of adverse event reports from the FDA FAERS database (2004-2024). [PDF]

BMC Pediatr
Song B, Zhang P, Chen S, Zhang Y, Hu J.
europepmc   +1 more source

DRUGS WHICH ANTAGONIZE 5‐HYDROXYTRYPTAMINE

, 1954
J. H. Gaddum, Khan A. Hameed
openalex   +1 more source

Knockout of the mitoribosome rescue factors Ict1 or Mtrfr is viable in zebrafish but not mice: compensatory mechanisms underlying each factor's loss

FEBS Open Bio, EarlyView.
Mitochondria contain two mitoribosome rescue factors, ICT1 and MTRFR (C12orf65). ICT1 also functions as a mitoribosomal protein in mice and humans, and its loss is lethal. Although Mtrfr knockout mice could not be generated, knockout zebrafish lines for ict1 and mtrfr were established.
Nobukazu Nameki, Chika Tomisawa, Soichiro Hoshino, Hidehiko Shimizu, Masashi Abe, Sho Arai, Kanako Kuwasako, Naoki Asakawa, Yusuke Inoue, Takuro Horii, Izuho Hatada, Masakatsu Watanabe   +11 more
wiley   +1 more source

An investigation of fentanyl and methamphetamine use among first-time arrestees from 25 county jails across the U.S. in 2023. [PDF]

Addict Sci Clin Pract
Schumacher JE, Ahsan A, Simpler AH, Natoli AP, Cain BJ, Chindavong PS, Yarcan A.   +6 more
europepmc   +1 more source

Identifying prognostic targets in metastatic prostate cancer beyond AR

FEBS Open Bio, EarlyView.
Genome‐wide functional screens combined with a large gene expression database and clinical outcomes can identify new therapeutic vulnerabilities in prostate cancer. Eight potentially druggable targets demonstrated strong dependency in cell lines, were associated with worse prognosis clinically, and showed evidence of protein expression in prostate ...
Emily Feng, Eric Feng, Tracy Berg, Isabella S. Nguyen, Lilac G. Nguyen, William Chen, Meng Zhang, David Quigley, Marina Sharifi, Haolong Li, Ilsa Coleman, Peter S. Nelson, Martin Sjöström, Shuang G. Zhao   +13 more
wiley   +1 more source

Report on Drugs [PDF]

Journal of AOAC INTERNATIONAL, 1925
openaire   +1 more source

Deep learning-driven drug response prediction and mechanistic insights in cancer genomics. [PDF]

Sci Rep
Yu G, Fan Q.
europepmc   +1 more source

Construction of hyperthermostable d‐allulose 3‐epimerase from Arthrobacter globiformis M30 using the sequence information from Arthrobacter psychrolactophilus

FEBS Open Bio, EarlyView.
d‐Allulose can be produced from d‐fructose by d‐allulose 3‐epimerase. Based on sequence homology information, we successfully engineered thermostable mutants with the protein engineering method. By integrating positive mutations, we constructed an enzyme that exhibits hyperthermostability without a loss in the activity.
Kensaku Shimada, Kouhei Ohtani, Pushpa Kiran Gullapalli, Kazuhiko Ishikawa   +3 more
wiley   +1 more source